Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shigeru Tanzawa has a total of 123 co-authors. Here are the top co-authors by number of shared publications:

  • Nobuhiko Seki

    Division of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan

    7 shared publications
  • Toshihiro Misumi

    Department of Data Science, National Cancer Center Hospital East, Kashiwa, Chiba, Japan

    5 shared publications
  • Hisashi Tanaka

    Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan

    4 shared publications
  • Kiyotaka Watanabe

    Division of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Itabashi 173-8606, Japan

    4 shared publications
  • Nobuhisa Ishikawa

    Department of Respiratory Medicine, Hiroshima Prefectural Hospital, Minami-ku, Hiroshima, Japan

    4 shared publications
  • Shoichi Kuyama

    Department of Respiratory Medicine, National Hospital Organization Iwakuni Clinical Center, Yamaguchi, Japan

    4 shared publications

Latest Publications

  • Open Access

    Prognostic Impact of Baseline Neutrophil-to-Lymphocyte Ratio and Its On-Treatment Change on Survival Outcomes in Advanced Small-Cell Lung Cancer: A Retrospective Analysis

    by Masashi Ishihara, Hao Chen, Reina Asaga, Hikaru Suzuki, Shinichiro Yamamoto, Maju Kawamoto, Hitoshi Hoshiya, Hiroki Kazahari, Ryosuke Ochiai, Shigeru Tanzawa, et al.

    Background: Reliable and readily accessible prognostic biomarkers for extensive-stage small-cell lung cancer (ES-SCLC) are still lacking. The neutrophil-to-lymphocyte ratio (NLR), a marker of systemic inflammation, has shown prognostic relevance in several malignancies; however, its dynamic changes during treatment have not been well characterized in SCLC. Methods: We retrospectively analyzed patients with ES-SCLC who received systemic chemotherapy between January 2010 and December 2024. Baseline NLR was calculated within 7 days before first-line treatment, and on-treatment NLR was assessed at 6 weeks. A predefined NLR cutoff value of 5 was applied, and changes in NLR (ΔNLR) were defined as the difference between 6-week and baseline values. Associations with time to treatment failure (TTF) and overall survival (OS) were evaluated. Results: A total of 176 patients were enrolled. High baseline NLR (≥5) was significantly associated with shorter TTF and OS (both p < 0.01). An increase in NLR during treatment (ΔNLR ≥ 0) was significantly associated with poorer OS. Combined assessment of baseline NLR and ΔNLR identified distinct prognostic groups, with patients exhibiting both high baseline NLR and ΔNLR ≥ 0 demonstrating markedly poor survival. In multivariate analyses, baseline NLR, ΔNLR, performance status, and immune checkpoint inhibitor combination therapy were independent predictors of survival. Baseline NLR analyzed as a continuous variable showed a significant inverse correlation with TTF and OS. Conclusions: Combined evaluation of baseline NLR and its on-treatment change provides improved prognostic stratification in patients with ES-SCLC.


  • Open Access

    An Update on Therapeutic Strategies for HER2-Mutated Non-Small Cell Lung Cancer

    by Masashi Ishihara, Shigeru Tanzawa, Takeshi Honda, Yasuko Ichikawa, Kiyotaka Watanabe, Nobuhiko Seki

    Read the article titled "An Update on Therapeutic Strategies for HER2-Mutated Non-Small Cell Lung Cancer" on Journal of Clinical Question.

  • Open Access

    Clinical impact of hypomagnesemia induced by necitumumab plus cisplatin and gemcitabine treatment in patients with advanced lung squamous cell carcinoma: a subanalysis of the NINJA study

    by Shigeru Tanzawa, Hiroshige Yoshioka, Toshihiro Misumi, Eisaku Miyauchi, Kiichiro Ninomiya, Yasunori Murata, Masafumi Takeshita, Fumihiko Kinoshita, Takatoshi Fujishita, Shunichi Sugawara, et al.

    Background: The clinical impact of hypomagnesemia induced by necitumumab plus gemcitabine and cisplatin (GCN) as a second-line or later therapy is unclear. Objective: We aimed to evaluate the clinical characteristics and survival impact of hypomagnesemia induced by this therapy. Design: This was a sub-analysis of the retrospective multicenter NINJA study. Methods: Among the 93 patients enrolled in the NINJA study, this subanalysis included 75 patients with baseline serum magnesium concentrations. Results: The incidence of grade ⩾2 hypomagnesemia was 18.0% in the patients with normal baseline serum magnesium concentrations and 42.8% in those with low concentrations ( p = 0.073). The discontinuation rates of GCN treatment owing to hypomagnesemia in each group were 0% and 7.1%, respectively ( p = 0.187). The number of necitumumab doses and severity of hypomagnesemia were positively correlated ( r = 0.389, p < 0.001). Patients who developed hypomagnesemia in fewer than 21 days after the first dose of GCN ( n = 12) had significantly poorer progression-free survival (PFS) than those without the condition ( n = 63; median: 4.1 vs 4.4 months, p = 0.048). A similar trend was observed for OS (median: 9.7 vs 15.7 months, p = 0.062). These results were maintained after multivariate analyses (PFS: hazard ratio (HR) 2.46, p = 0.014; OS: HR 2.78, p = 0.021). Conclusion: GCN as a second-line or later therapy may be tolerable regardless of the patient’s baseline serum magnesium concentration. On the other hand, early serum magnesium reduction with this therapy is associated with a poor prognosis. However, caution should be needed because our results lacked sufficient information for confounding variables other than those analyzed here that may influence the correlation between hypomagnesemia and survival.


  • Open Access

    Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA Study

    by Yasunori Murata, Shigeru Tanzawa, Toshihiro Misumi, Hiroshige Yoshioka, Eisaku Miyauchi, Kiichiro Ninomiya, Masafumi Takeshita, Kensaku Ito, Tatsuro Okamoto, Shunichi Sugawara, et al.


  • Staphylococcus haemolyticus attenuates the antibacterial effect of teicoplanin via aggregates and biofilms

    by Yoshinori Sato, Nami Hatayama, Shigeru Tanzawa, Yoshitaka Kimura, Yoshitaka Wakabayashi, Takatoshi Kitazawa, Nobuhiko Seki, Yusuke Yoshino


  • Open Access

    A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study): primary analysis

    by Hisashi Tanaka, Shigeru Tanzawa, Toshihiro Misumi, Tomonori Makiguchi, Megumi Inaba, Takeshi Honda, Junya Nakamura, Koji Inoue, Takayuki Kishikawa, Masanao Nakashima, et al.

    Background: The standard of care for unresectable, locally advanced non-small-cell lung cancer (LA-NSCLC) is chemoradiotherapy (CRT) followed by durvalumab, based on the PACIFIC study. Although multiple Japanese phase II studies have shown high efficacy and tolerability of CRT with cisplatin plus S-1 (SP), no prospective study using durvalumab after SP-based CRT has been reported. Objectives: We conducted a multicenter phase II study of this approach, the interim analysis of which showed a high transition rate to durvalumab consolidation therapy. Here, we report the primary analysis results. Design: In treatment-naïve LA-NSCLC, cisplatin (60 mg/m2, day 1) and S-1 (80–120 mg/body, days 1–14) were administered with two 4-week cycles with concurrent thoracic radiotherapy (60 Gy) followed by durvalumab (10 mg/kg) every 2 weeks for up to 1 year. Methods: The primary endpoint was 1-year progression-free survival (PFS). The expected 1-year PFS and its lower limit of the 80% confidence interval (CI) were set as 63% and 47%, respectively, based on the results of TORG1018 study. Results: In all, 59 patients were enrolled, with 51 (86.4%) proceeding to durvalumab. The objective response rate throughout the study was 72.9% (95% CI: 59.7–83.6%). After median follow-up of 21.9 months, neither median PFS nor OS was reached. The 1-year PFS was 72.5% (80% CI: 64.2–79.2%, 95% CI: 59.1–82.2%), while the 1-year overall survival was 91.5% (95% CI: 80.8–96.4%). No grade 5 adverse events were observed throughout the study. The most common adverse event during the consolidation phase was pneumonitis (any grade, 78.4%; grade ⩾3, 2.0%). Eventually, 52.5% of patients completed 1-year durvalumab consolidation therapy from CRT initiation. Conclusion: This study of durvalumab after SP-based CRT met its primary endpoint and found a 1-year PFS of 73% from CRT initiation. This study provides the first prospective data on the prognosis and tolerability of durvalumab consolidation from the initiation of CRT. Trial registration: Japan Registry of Clinical Trials, jRCTs031190127, registered 1 November, 2019, https://jrct.niph.go.jp/latest-detail/jRCTs031190127


  • Open Access

    Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study)

    by Shigeru Tanzawa, Tomonori Makiguchi, Sadatomo Tasaka, Megumi Inaba, Ryosuke Ochiai, Junya Nakamura, Koji Inoue, Takayuki Kishikawa, Masanao Nakashima, Keiichi Fujiwara, et al.

    Background: The standard of care for unresectable, locally advanced non-small cell lung cancer (LA-NSCLC) is chemoradiotherapy (CRT) followed by durvalumab, based on the PACIFIC trial. Disease progression and pneumonitis were reported as the main reasons to preclude the initiation of durvalumab in multiple retrospective studies. However, the transition rate and the reasons for failure to proceed to consolidation therapy with durvalumab after CRT were not evaluated prospectively. Although phase II studies in Japan have shown high efficacy and tolerability of CRT with cisplatin + S-1 (SP), no prospective study using durvalumab after SP-based CRT has yet been reported. We therefore conducted a phase II study to verify the efficacy and safety of durvalumab following SP-based CRT. In this interim analysis, we report the transition rate and the reasons for its failure. Methods: In treatment-naïve LA-NSCLC, cisplatin (60 mg/m2, day 1) and S-1 (80–120 mg/body, days 1–14) were administered with two 4-week cycles with concurrent thoracic radiotherapy (60 Gy) followed by durvalumab every 2 weeks for up to 12 months. The primary endpoint was 12 month progression-free survival rate. Results: Fifty-nine patients were enrolled, of whom 86.4% (51/59) proceeded to durvalumab. All of them initiated durvalumab within 42 days after CRT [median 18 days (range: 3–38)], including 27.5% (14/51) in <14 days. Common reasons for failure to proceed to durvalumab were disease progression (2/59, 3.4%) and adverse events (6/59, 10.2%). Among the latter cases, four resumed treatment and proceeded to durvalumab within 42 days on off-protocol. The objective response rate and the disease control rate were 62.7% and 93.2%, respectively. The incidences of ⩾grade 3 pneumonitis, febrile neutropenia, and esophagitis were 0%, 8.5%, and 3.4%, respectively. Conclusion: Regarding durvalumab after CRT, this interim analysis of the SAMURAI study clarified the high transition rate, early introduction, and reasons for failure to proceed to consolidation therapy, which were not determined in the PACIFIC trial. Trial registration: Japan Registry of Clinical Trials, jRCTs031190127, registered 1 November, 2019, https://jrct.niph.go.jp/latest-detail/jRCTs031190127 .


  • Open Access

    Effect of Adjuvant and Palliative Chemotherapy in Large Cell Neuroendocrine Carcinoma of the Lung: A Systematic Review and Meta-Analysis

    by Hao Chen, Masashi Ishihara, Nobuyuki Horita, Hiroki Kazahari, Ryusuke Ochiai, Shigeru Tanzawa, Takeshi Honda, Yasuko Ichikawa, Kiyotaka Watanabe, Nobuhiko Seki

    Background: Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare subset of lung carcinoma with poor overall survival. Methods: A systematic review following a meta-analysis of studies was performed to identify the effect of different selections of chemotherapy in LCNEC. Articles providing overall survival data for adjuvant chemotherapy or palliative chemotherapy for LCNEC were eligible. The odds ratio (OR) of mortality at one or two years after chemotherapy was evaluated. Results: A total of 16 reports were finally included in the quantitative synthesis, involving a total of 5916 LCNEC patients. Adjuvant chemotherapy was administered to 1303 patients, and palliative chemotherapy was administered to 313 patients using either a small cell lung cancer (SCLC) or a non-small cell lung cancer (NSCLC) regimen. The OR for adjuvant chemotherapy was 0.73 (95% confidence interval (CI): 0.59 to 0.89, p = 0.002). The SCLC regimen showed an OR of 0.52 (95% CI: 0.11 to 2.38, p = 0.40) after one year, and 0.32 (95% CI: 0.11 to 0.89, p = 0.03) after two years, compared with the NSCLC regimen. Conclusions: Adjuvant chemotherapy for pulmonary large cell neuroendocrine carcinoma improved the outcome after surgery. The SCLC regimen showed better survival than the NSCLC regimen as palliative chemotherapy.


  • Open Access

    Effectiveness of Cell-Free and Concentrated Ascites Reinfusion Therapy in the Treatment of Malignancy-Related Ascites: A Systematic Review and Meta-Analysis

    by Hao Chen, Masashi Ishihara, Nobuyuki Horita, Shigeru Tanzawa, Hiroki Kazahari, Ryusuke Ochiai, Takahiko Sakamoto, Takeshi Honda, Yasuko Ichikawa, Kiyotaka Watanabe, et al.

    Background: Malignancy-related ascites (MRA) is one of the symptoms causing discomfort in advanced cancer patients. Cell-free and concentrated ascites reinfusion therapy (CART) is one of the palliative treatments widely conducted in Japan only. Methods: A systematic review following a meta-analysis of CART was performed. The efficiency and adverse events were evaluated. Results: A total of 2567 patients and 6013 procedures of CART were identified in this study. The mean volume of MRA collected was 4.29 (95% confidence interval (CI) 3.47–5.11) L, and the volume reinfused after concentrating was 0.49 (95% CI 0.39–0.60) L. A total of 86.1 (95% CI 77.1–95.2) g protein and 42.9 (95% CI 36.0–50.0) g albumin was reinfused. The mean time to the next paracentesis was 20.7 (95% CI 15.6–25.8) days. The body weight was reduced by 3.38 (95% CI 1.90–4.86; p < 0.01) kg, and abdominal circumference was reduced by 7.86 (95% CI 6.58–9.14; p < 0.001) cm. Serum albumin increased an average of 0.14 (95% CI −0.01–0.28; p = 0.07) mg/dL the day after CART. Abdominal distension, dyspnea, and fatigue were alleviated by 6.0 (95% CI 5.59–6.51), 2.66 (95% CI 2.05–3.28), and 2.64 (95% CI 1.86–3.42) points using a numerical rating scale system ranging from 0 to 10. Overall, 17% (95% CI 0.03–0.31%) of patients had improved performance status after CART. Significant body temperature elevation was observed, at an average of 0.4 °C (95% CI 0.18–0.62 °C). Conclusions: CART might be a safe and effective palliative therapy in MRA and further clinical trials are necessary.


  • Open Access

    A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study)

    by Shigeru Tanzawa, Sunao Ushijima, Kazuhiko Shibata, Takuo Shibayama, Akihiro Bessho, Kyoichi Kaira, Toshihiro Misumi, Kenshiro Shiraishi, Noriyuki Matsutani, Hisashi Tanaka, et al.

    Background: Based on the results of the PACIFIC study, chemoradiotherapy followed by 1-year consolidation therapy with durvalumab was established as the standard of care for unresectable, locally advanced non-small-cell lung cancer (LA-NSCLC). However, some topics not foreseen in that design can be explored, including progression-free survival (PFS) and overall survival (OS) after the start of chemoradiotherapy, the proportion of patients who proceeded to consolidation therapy with durvalumab, and the optimal chemotherapeutic regimens. In Japan, the combination regimen of S-1 + cisplatin (SP), for which the results of multiple clinical studies have suggested a good balance of efficacy and tolerability, is frequently selected in clinical settings. However, the efficacy and safety of consolidation therapy with durvalumab following this SP regimen have not been evaluated. We therefore planned a multicenter, prospective, single-arm, phase II study. Methods: In treatment-naïve LA-NSCLC, two cycles of combination chemotherapy with S-1 (80–120 mg/body, Days 1–14) + cisplatin (60 mg/m2, Day 1) will be administered at an interval of 4 weeks, with concurrent thoracic radiotherapy (60 Gy). Responders will then receive durvalumab every 2 weeks for up to 1 year. The primary endpoint is 1-year PFS rate. Discussion: Compared with the conventional standard regimen in Japan, the SP regimen is expected to be associated with lower incidences of pneumonitis, esophagitis, and febrile neutropenia, which complicate the initiation of consolidation therapy with durvalumab, and have higher antitumor efficacy during chemoradiotherapy. Therefore, SP-based chemoradiotherapy is expected to be successfully followed by consolidation therapy with durvalumab in more patients, resulting in prolonged PFS and OS. Toxicity and efficacy results of the SP regimen in this study will also provide information important to the future establishment of the concurrent combination of chemoradiotherapy and durvalumab. Trial registration: Japan Registry of Clinical Trials, jRCTs031190127, registered 1 November 2019, https://jrct.niph.go.jp/latest-detail/jRCTs031190127